This risk assessment tool predicts risk of heart failure, ischemic heart disease, and stroke by age 50 among survivors of childhood cancer. It uses information from the CCSS papers, "Individual prediction of heart failure among childhood cancer survivors" (Chow et al., ...) and “Prediction of ischemic heart disease and stroke among childhood cancer survivors” (Chow et al, …) , which created clinically useful models with readily available demographic and cancer treatment information. These models were designed specifically for patients who have recently completed cancer treatment (5 years from cancer diagnosis). These models have been validated in separate groups of childhood cancer survivors: Emma Children's Hospital and Academic Medical Center (Amsterdam, the Netherlands), the St. Jude Lifetime Cohort Study, and the National Wilms Tumor Study.